ApicHope Pharmaceutical Co., Ltd

Total Valuation

ApicHope Pharmaceutical Co., Ltd carries a market capitalization of 18.29B, placing it among publicly traded companies globally. Its enterprise value stands at 24.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

ApicHope Pharmaceutical Co., Ltd currently has 451.69M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 20.18, and the price-to-book ratio stands at 20.47.

Enterprise Valuation

On an enterprise value basis, ApicHope Pharmaceutical Co., Ltd trades at an EV/EBITDA multiple of 19.27 and an EV/FCF ratio of 109.42. The EV/Sales ratio of 21.86 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.27 provides insight into valuation relative to core operating earnings.

Financial Position

ApicHope Pharmaceutical Co., Ltd maintains a current ratio of 1.33, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 134.08, indicating elevated leverage, while an interest coverage ratio of -10.41 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, ApicHope Pharmaceutical Co., Ltd has paid -105.59M in income taxes, reflecting an effective tax rate of 11.11.

Stock Price Statistics

ApicHope Pharmaceutical Co., Ltd's stock has declined approximately -23.58491% over the past 52 weeks. The 50-day moving average sits at 38.58, while the 200-day moving average is 40.70.

Income Statement

Over the trailing twelve months, ApicHope Pharmaceutical Co., Ltd generated 1.12B in revenue and converted that into -660.04M in net income, yielding earnings per share of -1.50. EBITDA reached -458.13M, while operating income came in at -458.13M.

Balance Sheet

ApicHope Pharmaceutical Co., Ltd holds 672.79M in cash and equivalents against 2.50B in total debt, resulting in a net debt position of 1.78B. Total book value stands at 1.11B, with working capital of 481.98M providing operational flexibility.

Cash Flow

After subtracting -186.01M in capital expenditures, free cash flow totaled -186.01M - equivalent to -0.41 per share.

Margins

ApicHope Pharmaceutical Co., Ltd operates with a gross margin of 50.87, reflecting its pricing power and cost economics. The operating margin of -40.85 and net profit margin of -58.85 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -3.49 indicates the proportion of earnings distributed to shareholders.

Stock Splits

ApicHope Pharmaceutical Co., Ltd's most recent stock split took place on May 24, 2023 with a 2:3 split ratio.

Scores

ApicHope Pharmaceutical Co., Ltd posts an Altman Z-Score of 4.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.